Is Bangalore achieving herd immunity

Rajeev M. Patil, Aparna Kethineni, Arindam Mukhopadhyay, Saral Thangam


The emergence of a novel coronavirus (SARS-CoV-2) in late 2019 has led to millions of infections and substantial morbidity and mortality across the world. COVID-19 caused by SARS-CoV-2 infection ranges from mild self-limiting disease to acute respiratory distress syndrome and death. India is presently reeling under the second wave of COVID-19 pandemic with more than 2,52,28,996 cases and 2,78,719 deaths as of 18 May, 2021 making it the country with highest reporting cases in the world. Till that date, Bangalore, the capital city of Karnataka alone reported a total of 22,42,065 COVID-19 positive cases overstretching Indian Health care system in this pandemic situation. Considering its high population densities and contact rates it poses a challenge for controlling COVID-19 which is transmitted directly from person to person. The question of herd immunity and how soon it would develop therefore appears to be highly relevant in the context of disease elimination programs.


COVID-19, Herd immunity, Antibody titre

Full Text:



Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-41.

Neagu M. The bumpy road to achieve herd immunity in COVID-19. J Immunoassay Immunochem. 2020;41(6):928-45.

Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS-CoV-2 Control. JAMA. 2020;324(20):2095-6.

The Times of India. Over 1/4th in Karnataka infected by September: Survey, 2020. Available at: Accessed on 17 May 2021.

Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021;9(3):257-66.

George CE, Inbaraj LR, Chandrasingh S, Witte LP. High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond?. Epidemiol Infect. 2021;149:1-6.

Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology. 2006;11(1):49-53.

Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Nsour M, et al. Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg Infect Dis. 2016;22(10):1824-6.

Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining?. Front Immunol. 2020;11:586781.